Until the past decade, therapeutic options for unresectable and/or metastatic renal cell carcinoma were limited. Renal cell carcinoma is generally resistant to conventional chemotherapy, and only a small percentage of patients with renal cell carcinoma benefit from cytokine treatment. Since 2005, the advances in target-based therapy and immunotherapy modalities have created a paradigm shift in the treatment of renal cell carcinoma. Herein, we review the most up-to-date practices and emerging therapies for the treatment of renal cell carcinoma and focus on the threrapy caused side-effects and side-effect management.
|Translated title of the contribution||Targeted treatment of renal cell carcinoma, treatment caused side-effects and side-effect management|
|Number of pages||15|
|Publication status||Published - Sep 1 2017|
ASJC Scopus subject areas